Bleeding
Meta-analysis: Dual therapy yields less bleeding than triple therapy in AF, CAD

Dual antithrombotic therapy conferred less bleeding but similar rates of mortality, stroke, nonfatal MI and stent thrombosis compared with triple antithrombotic therapy in patients with atrial fibrillation and concomitant CAD, according to a meta-analysis published in The American Journal of Cardiology.
TWILIGHT: Switching to ticagrelor monotherapy 3 months post-PCI lowers bleeding vs. DAPT

SAN FRANCISCO — Among patients who had PCI with a drug-eluting stent and were on dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy lowered bleeding risk without raising ischemic risk compared with continued DAPT, according to results of the TWILIGHT trial presented at TCT 2019.
PCI increases risk for in-hospital mortality in octogenarian patients
Extended edoxaban, dalteparin equally effective among patients with cancer, venous thromboembolism
Extended treatment with oral edoxaban appeared comparable to subcutaneous dalteparin in safety and effectiveness for prevention of recurrent venous thromboembolism and major bleeding among patients with active cancer, according to results of a post-hoc analysis published in Journal of Thrombosis and Haemostasis.